Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
721-740 of 1,782 trials

ILUVIEN® Eye Implant for Children with Uveitis

We are studying the safety and effectiveness of the ILUVIEN® eye implant in children aged 6 to under 18 with recurrent non-infectious uveitis. This research aims to understand how well the implant works and any possible side effects.

Posterior Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementOphthalmologyPediatrics

Soft-Tissue Sarcoma: Intensified Chemotherapy Study

We are investigating whether adding extra chemotherapy cycles helps high-risk patients with resectable soft-tissue sarcomas have better outcomes after surgery. This study compares the effects of different chemotherapy regimens on survival rates.

Resectable Non-Metastatic Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Advanced Sarcomas: Pembrolizumab and Cabozantinib Study

We are investigating the effects of a combination of pembrolizumab and cabozantinib in patients with advanced sarcomas. The goal is to see if this treatment can help prevent disease progression and improve overall outcomes.

Advanced Metastatic Sarcomas>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Colorectal Cancer: Intermittent vs. Continuous Treatment with Panitumumab

We are studying whether an intermittent treatment of Panitumumab with FOLFIRI is as effective as continuous treatment for patients with metastatic left-sided colorectal cancer. The trial also aims to assess safety and quality of life for participants.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Autoimmune Diseases: Ublituximab Administration Study

We are evaluating how well ublituximab works when given through an IV or as a subcutaneous injection in patients with autoimmune diseases. This study aims to understand the drug's effects and how it moves through the body.

Relapsing Multiple SclerosisMyasthenia Gravis1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

Guselkumab for Kids with Inflammatory Conditions

We are studying the long-term safety of guselkumab in children with ulcerative colitis, Crohn’s disease, or juvenile psoriatic arthritis. This research aims to ensure the medication is safe for young patients.

Crohn's DiseaseJuvenile Psoriatic ArthritisUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementDermatologyGastroenterologyRheumatology

Tick-Borne Encephalitis: Novel Cytokine Release Assay

We are studying a new test to measure immune responses to Tick-Borne Encephalitis in healthy and immunosuppressed individuals. This research aims to improve understanding of how well the immune system responds to the virus and vaccination.

Tick-borne Encephalitis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesAllergologyInfectious Diseases

Pleural Mesothelioma: Pembrolizumab with Chemotherapy

We are studying a combination of pembrolizumab and standard chemotherapy for patients with resectable epithelioid and biphasic pleural mesothelioma. The goal is to see if this treatment improves response rates and overall survival.

Malignant Pleural Mesothelioma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Ovarian and Breast Cancer: zAvatar Test Study

We are exploring whether the zAvatar test can help guide treatment decisions for patients with relapsed ovarian cancer and metastatic breast cancer. This study compares outcomes from the zAvatar test approach to standard care.

Breast CancerOvarian CancerMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Ulcerative Colitis: Oral Mesalazine Treatment

We are studying an oral medication for people with mild to moderate ulcerative colitis to see if it helps induce remission of symptoms. The trial will assess various measures of improvement after treatment.

Ulcerative Colitis3-6 monthsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Bipolar Disorder Type II: Lithium vs. Lamotrigine Study

We are comparing the effects of lithium and lamotrigine on mood stabilization in people with bipolar disorder type II. The goal is to see which treatment may better reduce symptoms and improve daily functioning.

Bipolar Disorder, Type II1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemotePsychiatry

Hamstring Injury: Hyperbaric Oxygen Therapy Study

We are investigating whether hyperbaric oxygen therapy helps athletes and military personnel recover faster from hamstring injuries. The study will also look at safety and changes in injury over time.

Hamstring InjuryConfirmation phase (III)No PlaceboStandard MedicinesOrthopedics and Traumatology

Alzheimer's Disease: Efavirenz Study

We are investigating whether Efavirenz can affect certain biomarkers in people with early Alzheimer's Disease. This study aims to understand its safety and how it works in the body.

Alzheimer's Disease3-6 monthsSafety phase (I)Efficacy phase (II)Standard MedicinesNeurology

Crohn's Disease: Upadacitinib for Children

We are studying the effects of Upadacitinib in children with active Crohn's disease who haven't had success with other treatments. The goal is to see if it helps them achieve better health outcomes.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Psoriasis Management: Proactive Drug Monitoring Study

We are comparing proactive drug monitoring to standard care for people with moderate to severe psoriasis. The goal is to see if proactive monitoring helps maintain better disease control and improves quality of life.

Moderate-to-Severe Psoriasis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyDermatology

Peripheral T Cell Lymphoma: LIS1 Antibody Study

We are testing a new antibody treatment for patients with relapsed or refractory peripheral T cell lymphoma. The study aims to evaluate its safety and effectiveness in fighting this type of cancer.

Peripheral T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

High-Risk Neuroblastoma: Dinutuximab Beta with Chemotherapy

We are studying the safety and effectiveness of combining dinutuximab beta with two chemotherapy regimens for children with newly diagnosed high-risk neuroblastoma. This research aims to improve treatment options and outcomes for these young patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Ulcerative Colitis: Tofacitinib for Children

We are studying whether the oral medication tofacitinib can help children with moderately to severely active ulcerative colitis achieve remission. The trial will also look at how well the medication works and how it is accepted by young patients.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Ponatinib for Pediatric Leukemias and Solid Tumors

We are studying the safety and effectiveness of ponatinib in children with recurrent or hard-to-treat leukemias and solid tumors. This trial aims to help those who have not responded to other therapies.

Acute Myeloid LeukaemiaChronic Myeloid Leukaemia1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Sepsis Treatment: Meropenem vs. Piperacillin/Tazobactam

We are comparing two antibiotics to see which one may help critically ill adults with sepsis survive better and improve their health outcomes.

Septic ShockSepsis6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine